About Terminal nucleotidyltransferase 5D
Terminal nucleotidyltransferase 5D (TENT5D) is a protein
from Homo sapiens identified by UniProt accession
Q8NEK8, 389 residues long.
MolForge cross-references it against 0 known binders and
92 disease associations.
Target properties
| Protein name | Terminal nucleotidyltransferase 5D |
| UniProt accession | Q8NEK8 |
| Gene | TENT5D |
| Organism | Homo sapiens |
| Length | 389 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (92)
Diseases linked to this target (Open Targets).
- azoospermia · score 0.10
- male infertility with teratozoospermia due to single gene mutation · score 0.09
- partial chromosome Y deletion · score 0.07
- spermatogenic failure 64 · score 0.07
- spermatogenic failure 41 · score 0.07
- spermatogenic failure 39 · score 0.07
- spermatogenic failure 56 · score 0.07
- spermatogenic failure 65 · score 0.07
- spermatogenic failure 10 · score 0.07
- spermatogenic failure 11 · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8NEK8-F1 | alphafold | PREDICTED | 87.37 | — |
Amino-acid sequence (389 residues)
MSEIRFTNLT WDQVITLDQV LDEVIPIHGK GNFPTMEVKP KDIIHVVKDQ LIGQGIIVKD ARLNGSVASY ILASHNGISY KDLDVIFGVE LPGNEEFQVV KDAVLDCLLD FLPKDVKKEK LSPDIMKDAY VQKLVKVCNG HDCWSLISLS NNTGKNLELK FVSSLRRQFE FSVDSFQIVL DPMLDFYSDK NAKLTKESYP VVVAESMYGD FQEAMTHLQH KLICTRKPEE IRGGGLLKYC SLLVHGFKPA CMSEIKNLER YMCSRFFIDF PHIEEQQKKI ESYLHNHFIG EGMTKYDYLM TLHGVVNEST VCLMSYERRQ ILHLITMMAL KVLGELNILP NTQKVTCFYQ PAPYFAAEAR YPIYVIPEPP PVSFQPYHPL HFRGSNGMS
Explore Terminal nucleotidyltransferase 5D with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets